查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
人類免疫缺乏病毒治療藥的全球市場:成長，未來展望，競爭分析 (2025年～2033年)
市場調查報告書
商品編碼
1645228

人類免疫缺乏病毒治療藥的全球市場:成長，未來展望，競爭分析 (2025年～2033年)

Human Immunodeficiency Virus Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2025 - 2033
出版日期: | 出版商: Acute Market Reports | 英文 178 Pages | 商品交期: 最快1-2個工作天內

價格

人類免疫缺乏病毒 (HIV) 藥物市場是製藥業的一個部門，專注於研究、開發和分銷針對 HIV（一種導致獲得性免疫缺陷症候群 (AIDS) 的病毒）的藥物和治療。自 20 世紀 80 年代發現以來，愛滋病毒/愛滋病已成為重大公共衛生威脅，導致全球數百萬人死亡。對有效治療的持續需求，加上醫學研究的進步，推動該市場走向傳染病治療的前沿。預計 2025 年至 2033 年期間人類免疫缺陷病毒治療市場複合年增長率為 1.3%。

推動因素：全球愛滋病毒/愛滋病發病率和盛行率不斷上升

毫無疑問，愛滋病毒治療市場成長的主要動力是全球愛滋病毒/愛滋病感染者數量的持續增加。根據聯合國愛滋病規劃署（UNAIDS）的數據，2019 年全球約有 3,800 萬人感染愛滋病毒。這一數字凸顯了有效治療的迫切性和需求。此外，某些地區，特別是撒哈拉以南非洲地區受到的影響尤其嚴重，全球必須加強對抗病毒的傳播和影響。作為應對，許多政府和國際組織加強了資金和措施的投入，進一步刺激了研究和治療的需求。

機會：新型治療方法的出現

新療法的開發為持續對抗愛滋病毒/愛滋病帶來了重大機會。近年來，人們對基因療法和 CRISPR 技術作為 HIV 的潛在治療或治癒方法的興趣日益濃厚。最近發表在科學期刊上的研究表明，這些方法有可能瞄準並消滅體內的愛滋病毒儲存庫。這些進步標誌著從傳統抗逆轉錄病毒療法向更明確、更具潛在治癒力的療法的範式轉變，為市場擴張帶來了巨大的機會。

阻礙因素：治療費用高昂和可近性問題

儘管取得了進展，但愛滋病毒藥物市場仍面臨著一個阻礙因素：高昂的治療費用往往限制了藥物的可及性，尤其是在中低收入國家。抗病毒療法雖然有效，但價格昂貴，發展中地區的衛生系統難以普遍提供這種療法。世界衛生組織（WHO）多次強調這種差距，指出雖然在改善治療機會方面取得了進展，但仍存在巨大差距，主要是由於晚期愛滋病毒藥物成本過高。

課題：治療依從性與抗藥性

愛滋病毒治療的主要課題之一是治療依從性和相關的抗藥性風險。愛滋病毒治療需要嚴格遵守用藥方案，任何疏忽都可能導致病毒對藥物產生抗藥性。這種抗藥性不僅威脅患者的健康，也導致抗藥性病毒的傳播，使治療方案變得複雜。美國疾病管制與預防中心（CDC）指出，抗藥性問題已成為亟待解決的問題，並列舉了由於不堅持治療而導致的愛滋病毒抗藥性問題的出現​​和傳播的例子。

依藥物類型分析

就藥品類型而言，市場分為品牌藥和仿製藥。到 2024 年，品牌藥銷售額將超過仿製藥銷售額。在製藥巨頭的大量研發投入、專利保護和廣泛行銷活動的支持下，這些品牌藥物在市場上佔據了重要的地位。特別是在專利法嚴格執行的地區，它是可靠性、有效性和創新的代名詞。然而，仿製藥預計將在 2025 年至 2033 年期間實現最高的複合年增長率。隨著幾種品牌愛滋病毒藥物的專利到期，仿製藥預計將變得更加普遍。這些仿製藥具有成本效益和高效性，並有望填補治療方面的空白，特別是在中低收入國家，因此成為成長最快的領域。

依藥物類別分析

根據藥物類別，HIV 治療方案由核苷類似物逆轉錄酶抑制劑 (NRTIs)、非核苷逆轉錄酶抑制劑 (NNRTIs)、進入/融合抑制劑、蛋白酶抑制劑 (PIs)、整合酶抑制劑和輔助受體拮抗劑組成。由於 NRTI 在市場上的長期存在及其在 HAART（高效抗逆轉錄病毒療法）中的基礎性作用，預計 2024 年 NRTI 將在銷售方面處於領先地位。幾十年來它一直是愛滋病治療的基石。然而，從 2025 年到 2033 年，整合酶抑制劑的主導地位預計將脫穎而出，預計將呈現最高的複合年增長率。轉向這些抑制劑與其效力、減少的副作用和快速降低病毒量的有效性有關，這已在多項臨床試驗中得到證實。

區域分析

從地理位置來看，由於強大的醫療基礎設施、較高的認知度以及在研發方面的大量投資，預計北美將在 2024 年佔據愛滋病治療藥物市場最大的收入佔有率。然而，2025 年至 2033 年的十年間，愛滋病毒感染率的重點可能會放在非洲，預計那裡的複合年增長率最高。預計這一增長將受到國際合作、醫療保健和基礎設施投資以及對可獲得且負擔得起的愛滋病毒治療的迫切需求的推動。

競爭趨勢

在競爭格局方面，2025 年將由 AbbVie Inc.、Boehringer Ingelheim International Inc.、Bristol-Myers Squibb Company、Cipla、Genentech, Inc.、Gilead Sciences, Inc.、Merck & Co., Inc. 和 ViiV Medical Inc. 等領先公司佔據主導地位。這些公司擁有強大的藥品管道、策略聯盟、病患權益保護計畫和顯著的市場主導地位。這些公司的策略通常包括積極研發、申請專利以及與當地公司合作以使藥品更為廣泛地普及。隨著我們邁向 2025 年及 2033 年，市場競爭格局預計將變得更加多樣化。隨著仿製藥的進入和本土製造商的崛起，尤其是在高需求領域，協作、創新和適應性已成為行業參與者的指導原則。

目錄

第1章 序文

  • 分析內容
    • 分析的目的
    • 對象者
    • 主要的提供內容
  • 市場區隔
  • 分析方法
    • 階段Ⅰ:二次調查
    • 階段Ⅱ:一次調查
    • 階段Ⅲ:有學識者檢討
    • 前提條件
    • 所採用的方法

第2章 摘要整理

第3章 人類免疫缺乏病毒治療藥市場:競爭分析

  • 主要供應商的市場定位
  • 供應商所採用的策略
  • 主要的產業策略

第4章 人類免疫缺乏病毒治療藥市場:常量分析和市場動態

  • 簡介
  • 全球人類免疫缺乏病毒治療藥市場 (以金額為準，2023～2033年)
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要課題
    • 主要的機會
  • 促進因素與阻礙因素的影響分析
  • Seesaw分析
  • 波特的五力分析
    • 供應商電力
    • 買主電力
    • 替代品的威脅
    • 新加入廠商業者的威脅
    • 競爭企業間的敵對關係
  • PESTEL分析
    • 政治形勢
    • 經濟形勢
    • 技術性形勢
    • 法律上的形勢
    • 社會形勢

第5章 人類免疫缺乏病毒治療藥市場:藥物類別 (2023～2033年)

  • 市場概要
  • 成長·收益分析:2024年 vs 2033年
  • 市場區隔
    • 品牌醫藥品
    • 學名藥

第6章 人類免疫缺乏病毒治療藥市場:各類藥物 (2023～2033年)

  • 市場概要
  • 成長·收益分析:2024年 vs 2033年
  • 市場區隔
    • 核苷類似物逆轉錄酶抑制劑 (NRTI)
    • 非核苷逆轉錄酶抑制劑（NNRTI）
    • 進入和融合抑制劑
    • 蛋白酶抑​​製劑（PI）
    • 整合酶抑制劑
    • 輔助受體拮抗劑

第7章 北美的人類免疫缺乏病毒治療藥市場 (2023～2033年)

  • 市場概要
  • 人類免疫缺乏病毒治療藥市場:藥物類別 (2023～2033年)
  • 人類免疫缺乏病毒治療藥市場:各類藥物 (2023～2033年)
  • 人類免疫缺乏病毒治療藥市場:各地區 (2023～2033年)
    • 北美
      • 美國
      • 加拿大
      • 其他北美地區

第8章 英國·EU各國的人類免疫缺乏病毒治療藥市場 (2023～2033年)

  • 市場概要
  • 人類免疫缺乏病毒治療藥市場:藥物類別 (2023～2033年)
  • 人類免疫缺乏病毒治療藥市場:各類藥物 (2023～2033年)
  • 人類免疫缺乏病毒治療藥市場:各地區 (2023～2033年)
    • 英國·EU各國
      • 英國
      • 德國
      • 西班牙
      • 義大利
      • 法國
      • 其他歐洲地區

第9章 亞太地區的人類免疫缺乏病毒治療藥市場 (2023～2033年)

  • 市場概要
  • 人類免疫缺乏病毒治療藥市場:藥物類別 (2023～2033年)
  • 人類免疫缺乏病毒治療藥市場:各類藥物 (2023～2033年)
  • 人類免疫缺乏病毒治療藥市場:各地區 (2023～2033年)
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳洲
      • 韓國
      • 其他亞太地區

第10章 南美的人類免疫缺乏病毒治療藥市場 (2023～2033年)

  • 市場概要
  • 人類免疫缺乏病毒治療藥市場:藥物類別 (2023～2033年)
  • 人類免疫缺乏病毒治療藥市場:各類藥物 (2023～2033年)
  • 人類免疫缺乏病毒治療藥市場:各地區 (2023～2033年)
    • 南美
      • 巴西
      • 墨西哥
      • 其他南美國家地區

第11章 中東·非洲的人類免疫缺乏病毒治療藥市場 (2023～2033年)

  • 市場概要
  • 人類免疫缺乏病毒治療藥市場:藥物類別 (2023～2033年)
  • 人類免疫缺乏病毒治療藥市場:各類藥物 (2023～2033年)
  • 人類免疫缺乏病毒治療藥市場:各地區 (2023～2033年)
    • 中東·非洲
      • GCC
      • 非洲
      • 其他中東·非洲地區

第12章 企業簡介

  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Genentech Inc.
  • Gilead Sciences Inc.
  • Merck & Co. Inc.
  • ViiV Healthcare
  • 其他
Product Code: 120-12-24

The human immunodeficiency virus (HIV) therapeutics market pertains to the sector of the pharmaceutical industry that focuses on the research, development, and distribution of treatments and drugs for HIV, the virus that leads to Acquired Immunodeficiency Syndrome (AIDS). Since its discovery in the 1980s, HIV/AIDS has posed a significant public health threat, resulting in millions of deaths worldwide. The consistent demand for effective treatments, combined with advancements in medical research, has propelled this market to the forefront of infectious disease therapeutics. human immunodeficiency virus therapeutics market is estimated to grow at a CAGR of 1.3% from 2025 to 2033.

Driver: Increased Global Incidence and Prevalence of HIV/AIDS

The undeniable, primary driver for the growth of the HIV therapeutics market has been the continual rise in the number of HIV/AIDS cases worldwide. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), around 38 million people were living with HIV globally in 2019. The sheer magnitude of this number underscores the urgency and demand for effective treatments. Additionally, certain regions, particularly Sub-Saharan Africa, have been disproportionately affected, intensifying the global efforts to combat the spread and repercussions of the virus. In response, numerous governments and international organizations have ramped up funding and initiatives, further driving the demand for research and therapeutics.

Opportunity: Emergence of Novel Therapeutic Approaches

As the fight against HIV/AIDS continues, one significant opportunity has been the development of novel therapeutic modalities. In recent years, there has been a growing interest in gene therapies and CRISPR technology as potential treatments or even cures for HIV. Recent studies, published in scientific journals, have illustrated the potential of these approaches to target and eradicate HIV reservoirs in the body. These advancements suggest a paradigm shift from traditional antiretroviral therapies to more definitive and potentially curative approaches, representing a significant opportunity for market expansion.

Restraint: High Treatment Costs and Accessibility Issues

Despite advancements, the HIV therapeutics market faces the restraint of high treatment costs, which often limits accessibility, especially in low- and middle-income countries. Antiretroviral treatments, while effective, can be expensive, making it challenging for healthcare systems in developing regions to provide them universally. The World Health Organization (WHO) has frequently highlighted this disparity, noting that while progress has been made in increasing access to treatment, significant gaps remain, primarily due to the prohibitive costs associated with advanced HIV drugs.

Challenge: Treatment Adherence and Drug Resistance

One of the critical challenges in HIV treatment is the issue of treatment adherence and the consequent risk of drug resistance. HIV treatment requires strict adherence to drug regimens, and any lapses can lead to the virus developing resistance to the medication. This resistance not only jeopardizes the patient's health but can also lead to the spread of drug-resistant strains of the virus, complicating treatment protocols. The Centers for Disease Control and Prevention (CDC) has flagged drug resistance as a pressing concern, citing instances where individuals, due to inconsistent treatment adherence, have developed and transmitted drug-resistant HIV strains.

Drug Type Insights

By drug type, the market can be dissected into branded drugs and generic drugs. In 2024, branded drugs overshadowed their generic counterparts in terms of revenue generation. These branded drugs, backed by heavy R&D investments, patent protections, and extensive marketing campaigns by pharmaceutical giants, carved a significant niche in the market. They were synonymous with trust, efficacy, and innovation, especially in regions with robust patent law enforcement. Nevertheless, from 2025 to 2033, generic drugs are projected to register the highest CAGR. As patents of several branded HIV drugs expire, the market is anticipated to witness a proliferation of generic versions. These generic drugs, cost-effective yet efficacious, promise to bridge the treatment accessibility gap, especially in low and middle-income countries, making them the fastest-growing segment.

Drug Class Insights

Transitioning to drug class segmentation, the HIV therapeutics landscape is a mosaic of Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry and Fusion Inhibitors, Protease Inhibitors (PIs), Integrase Inhibitors, and Coreceptor Antagonists. NRTIs, owing to their longer presence in the market and foundational role in Highly Active Antiretroviral Therapy (HAART), reigned supreme in revenue generation in 2024. They've been the cornerstone of HIV treatment for decades. Yet, the span from 2025 to 2033 is expected to underscore the prominence of Integrase Inhibitors, which are predicted to manifest the highest CAGR. The shift towards these inhibitors can be linked to their potency, reduced side effects, and efficacy in reducing viral loads rapidly, as documented in various clinical trials.

Regional Insights

On a geographical plane, the HIV therapeutics market in 2024 saw North America capturing the largest revenue share, driven by robust healthcare infrastructure, high awareness levels, and substantial investments in R&D. However, the decade from 2025 to 2033 is likely to spotlight the African region, which, despite its high HIV prevalence, is forecasted to experience the highest CAGR. The growth is expected to be fueled by international collaborations, investments in healthcare infrastructure, and a pressing demand for accessible and affordable HIV treatments.

Competitive Trends

In the competitive arena, 2025 had stalwarts like AbbVie Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Inc., Genentech, Inc., Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare dominating the scene. These companies, with their robust drug pipelines, strategic alliances, and patient assistance programs, had a significant hold on the market. Their strategies often encompassed aggressive R&D, patent acquisitions, and forging partnerships with local entities for broader drug accessibility. As the market treads into 2025 and beyond to 2033, a more diversified competitive landscape is anticipated. With the entry of generic drugs and the rise of local manufacturers, especially in high-demand regions, collaboration, innovation, and adaptability are set to be the guiding tenets for industry players.

Historical & Forecast Period

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Human Immunodeficiency Virus Therapeutics market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Human Immunodeficiency Virus Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

  • Market Segmentation
  • Drug Type
    • Branded Drugs
    • Generic Drugs
  • Drug Class
    • Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Entry and Fusion Inhibitors
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Coreceptor Antagonists
  • Region Segment (2023-2033; US$ Million)
  • North America
  • U.S.
  • Canada
  • Rest of North America
  • UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Human Immunodeficiency Virus Therapeutics market?
  • What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2033.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Human Immunodeficiency Virus Therapeutics market?
  • Which is the largest regional market for Human Immunodeficiency Virus Therapeutics market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Human Immunodeficiency Virus Therapeutics market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Human Immunodeficiency Virus Therapeutics market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Human Immunodeficiency Virus Therapeutics Market
  • 2.2. Global Human Immunodeficiency Virus Therapeutics Market, By Drug Type, 2024 (US$ Million)
  • 2.3. Global Human Immunodeficiency Virus Therapeutics Market, By Drug Class, 2024 (US$ Million)
  • 2.4. Global Human Immunodeficiency Virus Therapeutics Market, By Geography, 2024 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2024

3. Human Immunodeficiency Virus Therapeutics Market: Competitive Analysis

  • 3.1. Market Positioning of Key Human Immunodeficiency Virus Therapeutics Market Vendors
  • 3.2. Strategies Adopted by Human Immunodeficiency Virus Therapeutics Market Vendors
  • 3.3. Key Industry Strategies

4. Human Immunodeficiency Virus Therapeutics Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Human Immunodeficiency Virus Therapeutics Market Value, 2023 - 2033, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 5.3. Market Segmentation
    • 5.3.1. Branded Drugs
    • 5.3.2. Generic Drugs

6. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 6.3. Market Segmentation
    • 6.3.1. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    • 6.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 6.3.3. Entry and Fusion Inhibitors
    • 6.3.4. Protease Inhibitors (PIs)
    • 6.3.5. Integrase Inhibitors
    • 6.3.6. Coreceptor Antagonists

7. North America Human Immunodeficiency Virus Therapeutics Market, 2023-2033, USD (Million)

  • 7.1. Market Overview
  • 7.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
  • 7.3. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
  • 7.4.Human Immunodeficiency Virus Therapeutics Market: By Region, 2023-2033, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 7.4.1.1.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 7.4.1.2.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 7.4.1.3.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

8. UK and European Union Human Immunodeficiency Virus Therapeutics Market, 2023-2033, USD (Million)

  • 8.1. Market Overview
  • 8.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
  • 8.3. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
  • 8.4.Human Immunodeficiency Virus Therapeutics Market: By Region, 2023-2033, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.1.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.2.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.3.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.4.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.5.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.6.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

9. Asia Pacific Human Immunodeficiency Virus Therapeutics Market, 2023-2033, USD (Million)

  • 9.1. Market Overview
  • 9.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
  • 9.3. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
  • 9.4.Human Immunodeficiency Virus Therapeutics Market: By Region, 2023-2033, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.1.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.2.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.3.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.4.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.5.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.6.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

10. Latin America Human Immunodeficiency Virus Therapeutics Market, 2023-2033, USD (Million)

  • 10.1. Market Overview
  • 10.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
  • 10.3. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
  • 10.4.Human Immunodeficiency Virus Therapeutics Market: By Region, 2023-2033, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 10.4.1.1.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 10.4.1.2.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 10.4.1.3.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

11. Middle East and Africa Human Immunodeficiency Virus Therapeutics Market, 2023-2033, USD (Million)

  • 11.1. Market Overview
  • 11.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
  • 11.3. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
  • 11.4.Human Immunodeficiency Virus Therapeutics Market: By Region, 2023-2033, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 11.4.1.1.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 11.4.1.2.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 11.4.1.3.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

12. Company Profile

  • 12.1. AbbVie Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Boehringer Ingelheim International GmbH
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Bristol-Myers Squibb Company
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Cipla Inc.
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Genentech, Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Gilead Sciences, Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Merck & Co., Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. ViiV Healthcare
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Others
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 2 Global Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 3 North America Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 4 North America Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 5 U.S. Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 6 U.S. Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 7 Canada Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 8 Canada Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 9 Rest of North America Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 10 Rest of North America Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 11 UK and European Union Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 12 UK and European Union Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 13 UK Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 14 UK Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 15 Germany Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 16 Germany Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 17 Spain Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 18 Spain Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 19 Italy Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 20 Italy Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 21 France Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 22 France Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 23 Rest of Europe Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 24 Rest of Europe Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 25 Asia Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 26 Asia Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 27 China Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 28 China Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 29 Japan Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 30 Japan Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 31 India Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 32 India Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 33 Australia Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 34 Australia Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 35 South Korea Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 36 South Korea Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 37 Latin America Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 38 Latin America Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 39 Brazil Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 40 Brazil Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 41 Mexico Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 42 Mexico Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 43 Rest of Latin America Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 44 Rest of Latin America Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 45 Middle East and Africa Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 46 Middle East and Africa Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 47 GCC Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 48 GCC Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 49 Africa Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 50 Africa Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)

List of Figures

  • FIG. 1 Global Human Immunodeficiency Virus Therapeutics Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Human Immunodeficiency Virus Therapeutics Market: Quality Assurance
  • FIG. 5 Global Human Immunodeficiency Virus Therapeutics Market, By Drug Type, 2024
  • FIG. 6 Global Human Immunodeficiency Virus Therapeutics Market, By Drug Class, 2024
  • FIG. 7 Global Human Immunodeficiency Virus Therapeutics Market, By Geography, 2024
  • FIG. 8 Market Geographical Opportunity Matrix - Global Human Immunodeficiency Virus Therapeutics Market, 2024
  • FIG. 9Market Positioning of Key Human Immunodeficiency Virus Therapeutics Market Players, 2024
  • FIG. 10 Global Human Immunodeficiency Virus Therapeutics Market, By Drug Type, 2024 Vs 2033, %
  • FIG. 11 Global Human Immunodeficiency Virus Therapeutics Market, By Drug Class, 2024 Vs 2033, %